Medical news
-
WFH Endorses NHF-McMaster Guideline on Care Models for Hemophilia Management
A number of national and international guidance documents, including the WFH Guidelines for the Management of Hemophilia, have supported integrated care as the optimal model...
-
SIPPET study results published in New England Journal of Medicine
May, 2016 – The results of the SIPPET (Survey of Inhibitors in Plasma-Products Exposed Toddlers) study were published today in the New England Journal of...
-
EMA committee completes review of Kogenate Bayer/Helixate NexGen studies
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has completed a review of data examining the risk of inhibitors associated with...
-
vCJD case reported in patient with a different genotype
The first case of variant Creutzfeldt-Jakob disease (vCJD) in a patient that is genetically different from all previous confirmed cases has been been reported in...
-
EMA investigating rare adverse events associated with hepatitis C treatment
The European Medicines Agency (EMA) has started a review of medicines known as direct-acting antivirals used for treating chronic hepatitis C infection. There have been...
-
Generating evidence to support clinical management and ensure access
We have entered an era of unprecedented growth in treatment options for hemophilia. A number of new treatments have, or will soon, enter the market,...
-
Access barrier to groundbreaking hepatitis C treatments
New medications unveiled in the last two years have revolutionized the treatment of hepatitis C (HCV) drastically improving patients’ chances of a cure. The challenge...
-
Providing guidance on product selection
There are several new treatment products for bleeding disorders available today and over the next couple of years, even more will likely become available to...
-
World Federation of Hemophilia product selection statement
The selection of safe, effective medicinal products is the responsibility of national regulatory and health agencies. In the case of clotting factor concentrates, whether plasma-derived...
-
WFH statement on end-product testing
End-product testing cannot be used to assure viral safety of clotting factor concentrates. The testing used for screening plasma for viral agents, whether performed on...
